Nabriva Therape Ads (NBRV) |
|
1.79 0.04 (2.29%)
|
03-07 04:45 |
|
Open: |
1.75 |
Pre. Close: |
1.75 |
|
High:
|
1.84 |
Low:
|
1.52 |
|
Volume:
|
3,482,013 |
Market Cap:
|
62M |
|
|
|
|
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; for the treatment of acute bacterial skin and skin structure infection; and that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, osteomyelitis, and prosthetic joint infections. It is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.841 - 1.85 |
1.85 - 1.858 |
|
Low:
|
1.501 - 1.51 |
1.51 - 1.518 |
|
Close:
|
1.774 - 1.789 |
1.789 - 1.804 |
|
Technical analysis |
as of: 2021-03-05 5:11:04 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 3.20  One year: 4.08 |
| Support: |
Support1: 1.52 Support2: 1.26 |
| Resistance: |
Resistance1: 2.74 Resistance2: 3.49 |
| Pivot: |
2.51 |
| Moving Average: |
MA(5): 1.87 MA(20): 2.67
MA(100): 3.57 MA(250): 5.43 |
| MACD: |
MACD(12,26): -0.30 Signal(9): -0.18 |
| Stochastic oscillator: |
%K(14,3): 7.75 %D(3): 5.89 |
| RSI: |
RSI(14): 24.52 |
| 52-week: |
High: 14.10 Low: 1.52 Change(%): -86.6 |
| Average Vol(K): |
3-Month: 163632 10-Days: 420396 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.NBRV has closed above bottom band by 15.4%. Bollinger Bands are 69.7% wider than normal. The large width of the bands suggest high volatility as compared to NBRV's normal range. The bands have been in this wide range for 3 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Thu, 25 Feb 2021
Nabriva Therapeutics (NASDAQ:NBRV) Upgraded to "Buy" by Zacks Investment Research - MarketBeat
Mon, 01 Feb 2021
Nabriva Therapeutics Announces Retirement of its Chief Financial Officer - GlobeNewswire
Thu, 10 Dec 2020
Nabriva Therapeutics Announces Pricing of $15 Million Public Offering - GlobeNewswire
Thu, 10 Dec 2020
Nabriva Therapeutics Announces Proposed Public Offering Nasdaq:NBRV - GlobeNewswire
Mon, 07 Dec 2020
Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China - GlobeNewswire
Thu, 12 Nov 2020
Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
21 |
| Shares Float (M) |
15 |
|
% Held by Insiders
|
0.45 |
|
% Held by Institutions
|
20.72 |
|
Shares Short (K)
|
442 |
|
Shares Short P. Month (K)
|
645 |
Stock Financials |
|
EPS
|
-6.905 |
|
EPS Est This Year
|
-2.290 |
|
EPS Est Next Year
|
-1.990 |
|
Book Value (p.s.)
|
2.410 |
|
Profit Margin
|
|
|
Operating Margin
|
-2411.31 |
|
Return on Assets (ttm)
|
-59.5 |
|
Return on Equity (ttm)
|
-198.0 |
|
Qtrly Rev. Growth
|
-81.3 |
|
Gross Profit (p.s.)
|
-0.806 |
|
Sales Per Share
|
0.138 |
|
EBITDA (p.s.)
|
-3.291 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-73 |
|
Levered Free Cash Flow (M)
|
-47 |
Stock Valuations |
|
PE Ratio
|
-0.26 |
|
PEG Ratio
|
|
|
Price to Book value
|
0.74 |
|
Price to Sales
|
13.01 |
|
Price to Cash Flow
|
-0.51 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
